Global Gene Delivery Systems Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Gene Delivery Systems Market Research Report 2024
Gene Delivery System or Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
According to MRAResearch’s new survey, global Gene Delivery Systems market is projected to reach US$ 9760.3 million in 2033, increasing from US$ 7077.6 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gene Delivery Systems market research.
Gene Delivery System is widely used for Neurological Diseases, Cancer, etc. The Neurological Diseases occupied about 60% of market share, the cancer occupied about 35%.
North America is the largest consumption place, with a consumption market share nearly 62% in 2019. Following North America, Europe and Asia-Pacific occupied about 35% revenue market share in 2019.
Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen,Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute and etc. are the leaders of the industry. In 2019,top 3 companies occupied over 80% of revenue market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Gene Delivery Systems market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Amgen
Oxford BioMedica
SIBIONO
Shanghai Sunway Biotech
Roche
Pfizer
Bayer
Johnson & Johnson
Becton Dickinson
AstraZeneca
Baxter
HSCI
Epeius Biotechnologies
Segment by Type
Viral Gene Delivery System
Non-viral Gene Delivery System
Combined Hybrid System
Infectious Diseases
Oncology
Ophthalmology
Urology
Diabetes
CNS
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gene Delivery Systems report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Gene Delivery Systems market is projected to reach US$ 9760.3 million in 2033, increasing from US$ 7077.6 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gene Delivery Systems market research.
Gene Delivery System is widely used for Neurological Diseases, Cancer, etc. The Neurological Diseases occupied about 60% of market share, the cancer occupied about 35%.
North America is the largest consumption place, with a consumption market share nearly 62% in 2019. Following North America, Europe and Asia-Pacific occupied about 35% revenue market share in 2019.
Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen,Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute and etc. are the leaders of the industry. In 2019,top 3 companies occupied over 80% of revenue market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Gene Delivery Systems market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Amgen
Oxford BioMedica
SIBIONO
Shanghai Sunway Biotech
Roche
Pfizer
Bayer
Johnson & Johnson
Becton Dickinson
AstraZeneca
Baxter
HSCI
Epeius Biotechnologies
Segment by Type
Viral Gene Delivery System
Non-viral Gene Delivery System
Combined Hybrid System
Segment by Application
Infectious Diseases
Oncology
Ophthalmology
Urology
Diabetes
CNS
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gene Delivery Systems report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source